Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc., as noted in the metadata) on November 12, 2021. The report discloses the Company's financial results for the fiscal quarter ended September 30, 2021. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ANGN.
Key Financial Metrics
The filing text serves as a notification of results and incorporates the press release (Exhibit 99.1) by reference. The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing does not contain a comparative analysis or specific data points regarding material changes versus the prior comparable period within the body of the 8-K text.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the Exhibit 99.1 Press Release referenced in this filing.
- Confirm the Company name is Angion Biomedica Corp. (ANGN), noting the discrepancy with the metadata provided.
- Review the press release for any forward-looking statements or operational updates not captured in this summary.
- Check the Company's status as an Emerging Growth Company for potential differences in financial reporting standards.